Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug ...

Feb 24 (Reuters) - Drug compounders sued the U.S. Food and Drug Administration ... weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list, a move that will sharply curtail ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

While the Oscars highlighted outstanding achievements in filmmaking this past year, the red carpet sparked discussion about ...

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...